文献速递心血管胸部CT

高敏肌钙蛋白I与冠状动脉计算机断层扫描在疑似冠心病有症状门诊患者中的关联:来自PROMISE试验的启示

High-Sensitivity Troponin I and Coronary Computed Tomography in Symptomatic Outpatients With Suspected CAD: Insights From the PROMISE Trial.
PubMed 文献 · JACC Cardiovasc Imaging · 2018-03-14

在PROMISE试验中随机接受冠状动脉CTA的1844例稳定有症状疑似冠心病门诊患者中,测量高敏肌钙蛋白I浓度并分析其与阻塞性冠心病的关联;结果显示hsTnI浓度升高与冠状动脉粥样硬化的存在和严重程度增加相关。

要点

  • 98.5%的稳定有症状门诊患者可测得hsTnI,中位浓度1.5 ng/l
  • hsTnI位于较高四分位组者CAC评分更高、CAD更弥漫(均p<0.001)
  • 校正人口学与临床特征后,log转换hsTnI与CAD50(OR 1.15/四分位距,p=0.02)和CAD70(OR 1.25/四分位距,p=0.001)相关

核心结论

  • 在因疑似冠心病接受非急诊冠状动脉CTA的稳定有症状门诊患者中,较高的hsTnI浓度与冠状动脉粥样硬化的存在和严重程度增加相关。

研究设计与样本

  • PROMISE试验(前瞻性多中心影像研究评估胸痛)中随机接受冠状动脉CTA的1844例稳定有症状疑似冠心病门诊患者;hsTnI采用单分子计数法测量;参考标准为CTA所示的阻塞性CAD(CAD50为任何血管狭窄≥50%,CAD70为狭窄≥70%或左主干狭窄≥50%)。

关键影像表现/征象

  • hsTnI较高四分位组中CAC评分更高,CAD更常见且更弥漫(所有p<0.001)
  • hsTnI中位浓度为1.5 ng/l,98.5%的受试者可测得hsTnI
  • 6.1%的受试者hsTnI浓度≥该检测方法第99百分位浓度(6 ng/l)

诊断标准与关键数值

  • 阻塞性CAD50定义为任何血管狭窄≥50%,CAD70定义为狭窄≥70%或左主干狭窄≥50%
  • 校正人口学与临床特征后,log转换hsTnI浓度与CAD50相关(OR 1.15/四分位距,p=0.02)
  • 校正人口学与临床特征后,log转换hsTnI浓度与CAD70相关(OR 1.25/四分位距,p=0.001)
  • hsTnI浓度的独立预测因素包括年龄、性别和CAC评分(所有p<0.05)

临床应用与阅片要点

  • 在稳定有症状疑似冠心病门诊患者中,hsTnI浓度较高可能提示CAC评分更高及CAD更弥漫。
  • hsTnI浓度与阻塞性CAD的关联是在校正人口学与临床特征后得出的观察性关联。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The goal of this study was to examine associations between concentrations of high-sensitivity troponin I (hsTnI) (measured by using a single-molecule counting method) and obstructive coronary artery disease (CAD) in 1,844 stable, symptomatic outpatients with suspected CAD randomized to undergo coronary computed tomography angiography (CTA) in the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) trial.

BACKGROUND: Elevated concentrations of hsTnI are associated with CAD in patients with myocardial infarction. The meaning of hsTnI concentrations in stable symptomatic outpatients is not well understood.

METHODS: Clinical characteristics and CTA results (including coronary artery calcium [CAC] scores) were expressed across hsTnI quartiles. Determinants of hsTnI concentration were identified. Multivariable logistic regression identified independent predictors of obstructive CAD50 (≥50% stenosis in any vessel) and CAD70 (≥70% stenosis or ≥50% left main).

RESULTS: The median hsTnI concentration was 1.5 ng/l; nearly all (98.5%) subjects had measurable hsTnI, and 6.1% had concentrations ≥99th percentile concentration for this assay (6 ng/l). Higher CAC scores, as well as more prevalent and diffuse CAD, was seen in upper hsTnI quartiles (all p < 0.001). Independent predictors of hsTnI concentrations included age, sex, and CAC score (all p < 0.05). After adjusting for demographic and clinical characteristics, log-transformed hsTnI concentrations were associated with obstructive CAD50 (odds ratio: 1.15 per interquartile range; p = 0.02) and CAD70 (odds ratio: 1.25 per interquartile range; p = 0.001).

CONCLUSIONS: In stable symptomatic outpatients undergoing nonemergent coronary CTA for the diagnosis of suspected CAD, higher concentrations of hsTnI were associated with increasing presence and severity of coronary atherosclerosis. (Prospective Multicenter Imaging Study for Evaluation of Chest Pain [PROMISE]; NCT01174550).

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Januzzi JL, Suchindran S, Coles A, et al. High-Sensitivity Troponin I and Coronary Computed Tomography in Symptomatic Outpatients With Suspected CAD: Insights From the PROMISE Trial. JACC Cardiovasc Imaging. 2018. PMID: 29550314. doi:10.1016/j.jcmg.2018.01.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。